Rapid Ngn2-induction of excitatory neurons from hiPSC-derived neural progenitor cells.
- Authors
- Ho, Seok-Man; Hartley, Brigham J; Tcw, Julia; Beaumont, Michael; Stafford, Khalifa; Slesinger, Paul A; Brennand, Kristen J
- Year
- 2016
- Journal
- Methods (San Diego, Calif.)
- PMID
- 26626326
- DOI
- 10.1016/j.ymeth.2015.11.019
- PMCID
- PMC4860098
Since the discovery of somatic reprogramming, human induced pluripotent stem cells (hiPSCs) have been exploited to model a variety of neurological and psychiatric disorders. Because hiPSCs represent an almost limitless source of patient-derived neurons that retain the genetic variations thought to contribute to disease etiology, they have been heralded as a patient-specific platform for high throughput drug screening. However, the utility of current protocols for generating neurons from hiPSCs remains limited by protracted differentiation timelines and heterogeneity of the neuronal phenotypes produced. Neuronal induction via the forced expression of exogenous transcription factors rapidly induces defined populations of functional neurons from fibroblasts and hiPSCs. Here, we describe an adapted protocol that accelerates maturation of functional excitatory neurons from hiPSC-derived neural progenitor cells (NPCs) via lentiviral transduction of Neurogenin 2 (using both mNgn2 and hNGN2). This methodology, relying upon a robust and scalable starting population of hiPSC NPCs, should be readily amenable to scaling for hiPSC-based high-throughput drug screening.
Scheme of Ngn2-neuronal induction from human NPCs and the accelerated neuronal morphology of Ngn2-NPCs. (A) Schematic of mNgn2 and hNGN2 neuronal induction, starting from hiPSC-derived NPCs. (B) Representative bright-field images of hiPSCs, NPCs and mNgn2-induced neurons. Scale bar 100 ΞΌm. (C) Timeline of mNgn2 and hNGN2-neuronal induction strategy. (D) GFP images of NPCs transduced with GFP-PuroR lentivirus (images taken before and 24 h after doxycycline treatment). Scale bar 100 ΞΌm. (E) FACS quantification of the percentage of GFP-positive cells across ten NPC lines transduced with hNGN2-eGFP-PuroR (presented as the average of three NPC lines each from two controls, and one NPC line each from a third control as well as three schizophrenia patients). (F) GFP images of live GFP-, mNgn2- and hNGN2-transduced NPCs at various induction time points, showing that Ngn2-NPCs acquire neuronal morphology faster than GFP-NPCs. Scale bar 50 ΞΌm. (G) Averaged MAP2AB fluorescent intensity of GFP-, mNgn2 and hNGN2-induced neurons at three weeks induction. Error bars are SEM (Standard Error of the Mean). *p < 0.05, **p < 0.01, ***p < 0.001.
Accelerated increase in MAP2AB protein and RNA by Ngn2-transduction. (A) Representative images of mNgn2-induced neurons and GFP-NPCs at two weeks immunostained with neuronal dendrite marker MAP2AB (red), GFP (green) and DAPI-stained nuclei (blue). Scale bar 30 ΞΌm. (B) Averaged MAP2AB fluorescent intensity of GFP-NPCs and mNgn2-induced neurons at two weeks induction. MAP2AB intensity was normalized to total DAPI-positive nuclei per image, and further standardized to GFP-NPCs; mNgn2-induced neurons showed a 1.3-fold increase in MAP2AB intensity over GFP-NPCs. (C) Real-time qPCR analysis of MAP2AB mRNA expression from GFP-NPCs and mNgn2-induced neurons at two weeks of age. The expression level is normalized to GAPDH, and further standardized to GFP-NPCs; mNgn2-neurons showed 2.4-fold increase in MAP2AB. (D) Representative images of two-week-old and three-week-old mNgn2-induced neurons stained with MAP2AB (red) and DAPI (blue). Scale bar 30 ΞΌm. (E) Averaged MAP2AB fluorescent intensity of two-week-old and three-week-old mNgn2-induced neurons, normalized to two-week-old mNgn2-induced neurons; there was a 1.35-fold increased MAP2AB intensity in three-week-old mNgn2-induced neurons. Error bars are SEM (Standard Error of the Mean). *p < 0.05, **p < 0.01, ***p < 0.001.
Evoked activity recorded from Ngn2-induced neurons. (A) Voltage clamp recording shows putative voltage-gated Na+ (inward) and K+ (outward) currents. Voltage pulses shown below (β100 to +70 mV). Holding potential was β70 mV. (B) Current clamp recording from the same neuron shows evoked action potentials. Dashed line indicates β60 mV. Current injection pulses shown below (β16 pA to 48 pA).
Accelerated synaptic differentiation of Ngn2-induced neurons by neuronal induction. (A) Representative images of mNgn2-neurons and GFP-NPCs at three weeks, immunostained with presynaptic marker SYN1 (red) and MAP2AB (magenta). Scale bar 4 ΞΌm. (B) SYN1 puncta count, normalized to MAP2AB+ area, of mNgn2-induced neurons and GFP-NPCs at three weeks (gradual doxycycline withdrawal from day 2). The SYN1 puncta ratio was increased 1.9-fold relative to matched GFP-NPCs. (C) Real-time qPCR analysis of SYN1, vGLUT1, vGLUT2 and PSD95 mRNA expression from GFP-NPCs and mNgn2-induced neurons at three weeks, normalized to GAPDH, relative to GFP-NPCs. mNgn2-neurons showed increased SYN1 (2.3-fold), vGLUT1 (4.5-fold), vGLUT2 (3.8-fold); there no significant difference in PSD95 expression. (D) qPCR analysis of TH, GAD67, vGAT, TPH1, GFAP and S100Ξ² mRNA expression between three-week-old mNgn2-induced neurons and 6-week-old hiPSC forebrain (FB) neurons derived by directed differentiation; Ngn2-induced neurons showed decreased TH (6.3-fold), GAD67 (1.5-fold), comparably low levels of vGAT and TPH1, and decreased GFAP (13.6-fold) and S100Ξ²(3.2-fold) expression relative to 6-week-old forebrain neurons. (E) Representative images of 3-week-old mNgn2-induced neurons and PuroR-NPCs, stained with the dopaminergic marker TH, the GABAergic marker GAD65/67 and the astrocyte marker GFAP. DAPI-stained nuclei (blue). Scale bar 30 ΞΌm. (F) Representative bright-field images of 3-week-old hNGN2-induced neurons treated with 0 M, 10 nM, 50 nM, 100 nM and 1 ΞΌM Ara-C from days 6β20. Scale bar 30 ΞΌm. (G) Representative images of 3-weekβold hNGN2-induced neurons (from two independent controls) treated with 0 nM, 10 nM, 50 nM, and 100 nM Ara-C from days 6β20, stained with the replication marker Ki67. DAPI-stained nuclei (blue). Scale bar 30 ΞΌm. (H) Percentage of Ki67-positive cells in three-week-old Ngn2-induced neuron populations treated with between 0 and 100 nM Ara-C. Error bars are SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
Transient Ngn2 is sufficient to generate induced neurons. (A) Timeline of mNgn2-neuronal induction strategy with different doxycycline lengths. Doxycycline was withdrawn at day two (D2), day eight (D8), day fourteen (D14) or not at all (No W/D). (B) Representative images of three-week-old mNgn2-induced neurons immunostained with MAP2AB (red) and DAPI (blue). Scale bar 30 ΞΌm. (C) Average MAP2AB fluorescent intensity at three weeks. (D) Representative images mNgn2-induced neurons immunostained with the presynaptic marker SYN1 (red) and MAP2AB (magenta). Scale bar 4 ΞΌm. (E) SYN1 puncta count, normalized to MAP2AB+ area at three-weeks. (F) Real-time qPCR analysis of SYN1, vGLUT1, vGLUT2 and PSD95 mRNA expression at three-weeks. Error bars are SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
Electrical activity of Ngn2-induced neurons from NPCs. (A) 5-min MEA raster plot of spontaneous activity from a neural network of 14-day-old neurons, with 0-days (left panel) or 14-days (right panel) doxycycline treatment to induce mNgn2 expression. The response over multiple electrodes is a measurement of network connectivity. Each thin black line is representative of an action potential. Bursts of electrical activity are indicated with solid blue blocks. (B) The percentage of active electrodes per well (left panel) or percentage of spikes in bursts (right panel) following either 0 days (white bar), 2 days (pink bar), 8 days (light red) or 14 days (dark red) of doxycycline treatment to induce mNgn2 expression in 14-day-old neurons. (C) Total number of spikes (left panel) or mean firing rate (Hz) (right panel) following treatment with vehicle control (DMSO), picrotoxin (PTX), 6-cyano-7-nitroquinoxaline-2,3-dion (CNQX) and tetrodotoxin (TTX) on 21-day-old hNGN2-neurons. Error bars are SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
Inter-individual efficiencies in Ngn2-induction between NPC lines. Representative bright-field images of hNGN2-neurons from six individuals (three controls and three schizophrenia patients) over three independent experiments. Varying the initial seeding density of individual NPC lines (NPC plating densities inset) is required if achieving a consistent neuronal density at the end-point is desired.
| # | Section | Preview |
|---|---|---|
| 60 | 4. Discussion | In this study, we described a method by which mouse or human Ngn2 transduction can rapidly induce⦠|
| Name | Type |
|---|---|
| 24-well plate local | cohort |
| accutase | drug |
| action potential firing | phenotype |
| Allen Brain Span Atlas local | cohort |
| AquaPolymount mounting solution local | drug |
| Ara-C | drug |
| artificial cerebral spinal fluid (ACSF) local | drug |
| Ascl1 | gene |
| astrocytes | phenotype |
| astroglia | anatomy |
| blocking/permeabilization buffer local | drug |
| brain development | phenotype |
| Brn2 | gene |
| Ca2+ | drug |
| calcium chloride | drug |
| Cases_and_controls local | cohort |
| cDNA | drug |
| cell attachment local | phenotype |
| chloroform | drug |
| cholinergic neurons | phenotype |
| CNQX | drug |
| coating mixture local | drug |
| control GFP transduced NPCs local | cohort |
| controls | cohort |
| cortex | anatomy |
| culture medium | drug |
| CytosineΞ²-D-arabinofuranoside hydrochloride local | drug |
| DAPI | drug |
| DEPC-treated water local | drug |
| Dlg4 | gene |
| DMEM | drug |
| DNAse kit (Ambion, AM1907) local | drug |
| donkey serum | drug |
| dopaminergic neurons | anatomy |
| doxycycline | drug |
| Dulbecco's Modified Eagle Medium | drug |
| early fetal human cortical tissue local | anatomy |
| eGFP | drug |
| EGTA | drug |
| enhanced neuronal maturation local | phenotype |
| Fast SYBR green master mix local | drug |
| fetal forebrain tissue local | anatomy |
| forebrain | anatomy |
| forebrain NPCs local | anatomy |
| GABA | phenotype |
| GABAergic neuronal differentiation local | phenotype |
| GAD1 | gene |
| GAD65/67 local | phenotype |
| GFAP | gene |
| GFP | drug |
| glucose | drug |
| glutamatergic neurons | phenotype |
| growth factors | drug |
| HEK293T cells local | cohort |
| HEPES | drug |
| hiPSC-based induction local | cohort |
| hiPSCs local | drug |
| hNGN2 local | variant |
| hNGN2-induced neurons local | cohort |
| hNGN2-neurons local | cohort |
| induced neurons | phenotype |
| Isl1 | gene |
| isopropanol | drug |
| K+ channel local | drug |
| Ki67-positive replicative cells local | phenotype |
| laminin | drug |
| lentivirus | drug |
| LHX3 | gene |
| liquid nitrogen | drug |
| magnesium chloride | drug |
| MAP2 | gene |
| MAP2AB | gene |
| MAP2AB local | phenotype |
| matrigel | drug |
| MEA plate local | cohort |
| Mg2+ | drug |
| miR-124 | drug |
| miR-9 | drug |
| mNgn2 local | variant |
| mNgn2-induced neurons local | cohort |
| mNgn2-induced neurons local | phenotype |
| motor neuron identity local | phenotype |
| motor neurons local | phenotype |
| mouse brain | anatomy |
| Myt1l | gene |
| Na2ATP | drug |
| Na3GTP local | drug |
| Na+ channel local | drug |
| NaHCO3 | drug |
| Nanodrop | drug |
| Neural progenitor cells (NPC) local | cohort |
| neurite growth local | phenotype |
| neuroblast stage local | phenotype |
| NEUROD1 | gene |
| NEUROG2 | gene |
| neurogenesis | phenotype |
| neuronal activity | phenotype |
| neuronal differentiation | phenotype |
| neuronal fate | phenotype |
| neuronal induction local | phenotype |
| neuronal morphology | phenotype |
| neuron medium local | drug |
| neurons local | drug |
| neurons | phenotype |
| Neuropsychiatric_disorders local | phenotype |
| Ngn2 | gene |
| Ngn family local | gene |
| non-neuronal cell proliferation local | phenotype |
| NPC | drug |
| NPC-based induction local | cohort |
| NPC line local | cohort |
| NPC lines local | cohort |
| NPC medium local | drug |
| NPCs | cohort |
| NSB1442-4-3 local | cohort |
| NSB2513-1-4 local | cohort |
| NSB2607-1-4 local | cohort |
| NSB2607-3-1 local | cohort |
| NSB2607-4-1 local | cohort |
| NSB553-1-1 local | cohort |
| NSB553-2-3 local | cohort |
| NSB553-3-C local | cohort |
| NSB581-1-2 local | cohort |
| NSB690-1-4 local | cohort |
| paraformaldehyde | drug |
| PBSCa2+Mg2+ local | drug |
| PFA/medium mix local | drug |
| picrotoxin | drug |
| polyethylenimine | drug |
| poly-l-ornithine | drug |
| poly-ornithine | drug |
| postsynaptic maturation local | phenotype |
| potassium chloride | drug |
| potassium-D-gluconate local | drug |
| presynaptic maturation local | phenotype |
| primary antibody | drug |
| proliferative cells | phenotype |
| PSD95 | gene |
| psychiatric disorders | phenotype |
| PTX | drug |
| puromycin | drug |
| PuroR local | gene |
| reduced dendritic arborization local | phenotype |
| reduced synaptic density local | phenotype |
| resting potential local | phenotype |
| RNA | drug |
| RNABee local | drug |
| RNAse-free 75% ethanol local | drug |
| rtTa | drug |
| S100B local | gene |
| schizophrenia | phenotype |
| secondary antibody | drug |
| six independent individuals local | cohort |
| six-week-old hiPSC forebrain neurons local | cohort |
| Slc17a6 | gene |
| Slc17a7 | gene |
| SLC32A1 | gene |
| small molecules | drug |
| sodium chloride | drug |
| sodium creatine phosphate local | drug |
| sodium phosphate local | drug |
| SOX11 | gene |
| spinal cord | anatomy |
| Spinfection local | drug |
| study cohort | cohort |
| Superscript III reverse transcription kit (ThermoFisher Scientific, 11752-050) local | drug |
| SYN1 | gene |
| synaptogenesis | phenotype |
| TetO-hNGN2-P2A-eGFP-T2A-PuroR local | drug |
| TetO-hNGN2-P2A-PuroR local | drug |
| TetO-mNgn2-P2A-PuroR local | drug |
| tetrodotoxin | drug |
| Th | gene |
| three-week-old mNgn2-induced neurons local | cohort |
| TPH1 | gene |
| transduction efficiency local | phenotype |
| Triton-X | drug |
| TTX | drug |
| vGLUT1 | gene |
| vGLUT2 | gene |
| viral medium local | drug |
| VSVG local | gene |
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| 3D genetic architecture of schizophrenia risk across three neuronal subtypes. | Powell SK et al. | β | 2026 | β |
| A co-culture model of dopaminergic and glutamatergic neurons derived from patients with idiopathic schizophrenia reveals a hypodopaminergic phenotype. | Hartmann SM et al. | β | 2026 | β |
| Functional implications of polygenic risk for schizophrenia in human neurons. | Michael Deans PJ et al. | β | 2026 | β |
| Retinoic acid signaling regulates astrocyte reactivity by modulating MAPK/NF-ΞΊB pathways and mitochondrial integrity. | Yoo SH et al. | β | 2026 | β |
| Temporal proteomic and phosphoproteomic dynamics during neuronal differentiation in the reference iPSC line KOLF2.1J. | Hao Y et al. | β | 2026 | β |
| Transcriptomic and phenotypic convergence of neurodevelopmental disorder risk genes in vitro and in vivo. | Fernandez Garcia M et al. | β | 2026 | β |
| Uncovering NMDA receptor-mediated high firing activity in excitatory human neurons. | Gameiro-Ros I et al. | β | 2026 | β |
| ABCA7 variants impact phosphatidylcholine and mitochondria in neurons. | von Maydell D et al. | β | 2025 | β |
| An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome. | Thakur P et al. | β | 2025 | β |
| Cell culture research in aging and Alzheimer's disease: The strategic use/reuse of untreated controls and savings people's tax dollars. | Kshirsagar S et al. | β | 2025 | β |
| Drug treatment alters performance in a neural microphysiological system of information processing. | Watmuff B et al. | β | 2025 | β |
| Harnessing Intelligence from Brain Cells In Vitro. | Kagan BJ et al. | β | 2025 | β |
| Human CLOCK enhances neocortical function. | Liu Y et al. | β | 2025 | β |
| Human-Induced Pluripotent Stem Cells (iPSCs) for Disease Modeling and Insulin Target Cell Regeneration in the Treatment of Insulin Resistance: A Review. | Thiab S et al. | β | 2025 | β |
| Integrated multi-omic characterizations of the synapse reveal RNA processing factors and ubiquitin ligases associated with neurodevelopmental disorders. | Mei Y et al. | β | 2025 | β |
| K<sub>V</sub>7.2 channel dysfunction delays neuronal maturation and undermines early network development in a hiPSC model of KCNQ2-DEE. | Rosa F et al. | β | 2025 | β |
| Multiscale proteomic modeling reveals protein networks driving Alzheimer's disease pathogenesis. | Wang E et al. | β | 2025 | β |
| Neurodegenerative disease-associated microRNAs acting as signaling molecules modulate CNS neuron structure and viability. | Kumbol V et al. | β | 2025 | β |
| Neuron-reactive KIR<sup>+</sup>CD8<sup>+</sup> T cells display an encephalitogenic transcriptional program in autoimmune encephalitis. | Perriot S et al. | β | 2025 | β |
| Phenotypic complexities of rare heterozygous neurexin-1 deletions. | Fernando MB et al. | β | 2025 | β |
| Precision medicine approach for in vitro modeling and computational screening of anti-epileptic drugs in pediatric epilepsy patients with SCN2A (R1629L) mutation. | Kim J et al. | β | 2025 | β |
| Pulsed electromagnetic stimulation promotes neuronal maturation by up-regulating cholesterol biosynthesis. | Chen P et al. | β | 2025 | β |
| Subcellular proteomics and iPSC modeling uncover reversible mechanisms of axonal pathology in Alzheimer's disease. | Cai Y et al. | β | 2025 | β |
| The Life and Times of Brain Autophagic Vesicles. | Gambarotto L et al. | β | 2025 | β |
| Aberrant neuronal connectivity and network activity of neurons derived from patients with idiopathic schizophrenia. | Heider J et al. | β | 2024 | β |
| A comprehensive protocol for efficient differentiation of human NPCs into electrically competent neurons. | Romito E et al. | β | 2024 | β |
| Activity-Dependent Transcriptional Program in NGN2+ Neurons Enriched for Genetic Risk for Brain-Related Disorders. | Ma Y et al. | β | 2024 | β |
| An integrated in vitro human iPSCs-derived neuron and in vivo animal approach for preclinical screening of anti-seizure compounds. | Zhao C et al. | β | 2024 | β |
| Concerted transcriptional regulation of the morphogenesis of hypothalamic neurons by ONECUT3. | ZupanΔiΔ M et al. | β | 2024 | β |
| Deciphering the Pathophysiological Mechanisms Underpinning Myoclonus Dystonia Using Pluripotent Stem Cell-Derived Cellular Models. | Li Z et al. | β | 2024 | β |
| Defined co-cultures of glutamatergic and GABAergic neurons with a mutation in DISC1 reveal aberrant phenotypes in GABAergic neurons. | Heider J et al. | β | 2024 | β |
| ePRINT: exonuclease assisted mapping of protein-RNA interactions. | Hawkins S et al. | β | 2024 | β |
| Generation of a stably transfected mouse embryonic stem cell line for inducible differentiation to excitatory neurons. | Gu J et al. | β | 2024 | β |
| Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review. | Santarriaga S et al. | β | 2024 | β |
| Human stem cell-derived neurons and astrocytes to detect novel auto-reactive IgG response in immune-mediated neurological diseases. | Mathias A et al. | β | 2024 | β |
| Probing the molecular and cellular pathological mechanisms of schizophrenia using human induced pluripotent stem cell models. | Sebastian R et al. | β | 2024 | β |
| Senescent Astrocytes Derived from Human Pluripotent Stem Cells Reveal Age-Related Changes and Implications for Neurodegeneration. | Kim D et al. | β | 2024 | β |
| Supra- and sub-threshold intracellular-like recording of 2D and 3D neuronal networks using nanopillar electrode arrays. | Shukla S et al. | β | 2024 | β |
| Upregulated GIRK2 Counteracts Ethanol-Induced Changes in Excitability and Respiration in Human Neurons. | Prytkova I et al. | β | 2024 | β |
| Ξ²-Amyloid species production and tau phosphorylation in iPSC-neurons with reference to neuropathologically characterized matched donor brains. | Oakley DH et al. | β | 2024 | β |
| A Missense Variant in CASKIN1's Proline-Rich Region Segregates with Psychosis in a Three-Generation Family. | Wahbeh MH et al. | β | 2023 | β |
| Application-Oriented Bulk Cryopreservation of Human iPSCs in Cryo Bags Followed by Direct Inoculation in Scalable Suspension Bioreactors for Expansion and Neural Differentiation. | Meiser I et al. | β | 2023 | β |
| Elevated levels of FMRP-target MAP1B impair human and mouse neuronal development and mouse social behaviors via autophagy pathway. | Guo Y et al. | β | 2023 | β |
| Excitatory Neurons Derived from Human-Induced Pluripotent Stem Cells Show Transcriptomic Differences in Alzheimer's Patients from Controls. | Sagar R et al. | β | 2023 | β |
| Genetically modified cell spheroids for tissue engineering and regenerative medicine. | Jiang Z et al. | β | 2023 | β |
| Induction of dopaminergic neurons for neuronal subtype-specific modeling of psychiatric disease risk. | Powell SK et al. | β | 2023 | β |
| iPSC-derived reactive astrocytes from patients with multiple sclerosis protect cocultured neurons in inflammatory conditions. | Kerkering J et al. | β | 2023 | β |
| Mapping PTBP2 binding in human brain identifies SYNGAP1 as a target for therapeutic splice switching. | Dawicki-McKenna JM et al. | β | 2023 | β |
| Neurotransmitter release progressively desynchronizes in induced human neurons during synapse maturation and aging. | Uzay B et al. | β | 2023 | β |
| Non-additive effects of schizophrenia risk genes reflect convergent downstream function | Deans PM et al. | β | 2023 | β |
| Regulation of synaptic connectivity in schizophrenia spectrum by mutual neuron-microglia interaction. | Breitmeyer R et al. | β | 2023 | β |
| Reproducible Differentiation of Human Pluripotent Stem Cells into Two-Dimensional Cortical Neuron Cultures with Checkpoints for Success. | Waxman EA et al. | β | 2023 | β |
| TAT-LBD-Ngn2-improved cognitive functions after global cerebral ischemia by enhancing neurogenesis. | Feng B et al. | β | 2023 | β |
| The technology, opportunities, and challenges of Synthetic Biological Intelligence. | Kagan BJ et al. | β | 2023 | β |
| Transition from Animal-Based to Human Induced Pluripotent Stem Cells (iPSCs)-Based Models of Neurodevelopmental Disorders: Opportunities and Challenges. | Guerreiro S et al. | β | 2023 | β |
| Analysis of the circRNA and T-UCR populations identifies convergent pathways in mouse and human models of Rett syndrome. | Siqueira E et al. | β | 2022 | β |
| A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility. | Voloudakis G et al. | β | 2022 | β |
| AΞ²42 oligomers trigger synaptic loss through CAMKK2-AMPK-dependent effectors coordinating mitochondrial fission and mitophagy. | Lee A et al. | β | 2022 | β |
| Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons. | Sheta R et al. | β | 2022 | β |
| Making neurons, made easy: The use of Neurogenin-2 in neuronal differentiation. | Hulme AJ et al. | β | 2022 | β |
| Modeling gene Γ environment interactions in PTSD using human neurons reveals diagnosis-specific glucocorticoid-induced gene expression. | Seah C et al. | β | 2022 | β |
| Topologically controlled circuits of human iPSC-derived neurons for electrophysiology recordings. | Girardin S et al. | β | 2022 | β |
| Analysis framework and experimental design for evaluating synergy-driving gene expression. | Schrode N et al. | β | 2021 | β |
| Cell type-specific changes in transcriptomic profiles of endothelial cells, iPSC-derived neurons and astrocytes cultured on microfluidic chips. | Middelkamp HHT et al. | β | 2021 | β |
| Differential acute impact of therapeutically effective and overdose concentrations of lithium on human neuronal single cell and network function. | Izsak J et al. | β | 2021 | β |
| Efficient Derivation of Excitatory and Inhibitory Neurons from Human Pluripotent Stem Cells Stably Expressing Direct Reprogramming Factors. | Song S et al. | β | 2021 | β |
| Fitness selection of hyperfusogenic measles virus F proteins associated with neuropathogenic phenotypes. | Ikegame S et al. | β | 2021 | β |
| <i>MED12</i>-Related (Neuro)Developmental Disorders: A Question of Causality. | Plassche SV et al. | β | 2021 | β |
| Improved Method for Efficient Generation of Functional Neurons from Murine Neural Progenitor Cells. | Soni A et al. | β | 2021 | β |
| Intronic enhancer region governs transcript-specific <i>Bdnf</i> expression in rodent neurons. | Tuvikene J et al. | β | 2021 | β |
| Modulating the Electrical and Mechanical Microenvironment to Guide Neuronal Stem Cell Differentiation. | Oh B et al. | β | 2021 | β |
| Physiological and Pathological Ageing of Astrocytes in the Human Brain. | Verkerke M et al. | β | 2021 | β |
| SOX9-induced Generation of Functional Astrocytes Supporting Neuronal Maturation in an All-human System. | Neyrinck K et al. | β | 2021 | β |
| Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors. | Lagomarsino VN et al. | β | 2021 | β |
| Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimer's Disease. | Wang M et al. | β | 2021 | β |
| Using the dCas9-KRAB system to repress gene expression in hiPSC-derived <i>NGN2</i> neurons. | Li A et al. | β | 2021 | β |
| ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs. | Barretto N et al. | β | 2020 | β |
| Cell Type-Specific In Vitro Gene Expression Profiling of Stem Cell-Derived Neural Models. | Gregory JA et al. | β | 2020 | β |
| CRISPR-based functional evaluation of schizophrenia risk variants. | Rajarajan P et al. | β | 2020 | β |
| Doublecortin-like Kinase 1 Regulates Ξ±-Synuclein Levels and Toxicity. | VΓ‘zquez-VΓ©lez GE et al. | β | 2020 | β |
| Emerging Developments in Human Induced Pluripotent Stem Cell-Derived Microglia: Implications for Modelling Psychiatric Disorders With a Neurodevelopmental Origin. | Hanger B et al. | β | 2020 | β |
| Global Landscape and Dynamics of Parkin and USP30-Dependent Ubiquitylomes in iNeurons during Mitophagic Signaling. | Ordureau A et al. | β | 2020 | β |
| High-throughput screening identifies histone deacetylase inhibitors that modulate GTF2I expression in 7q11.23 microduplication autism spectrum disorder patient-derived cortical neurons. | Cavallo F et al. | β | 2020 | β |
| Integrating CRISPR Engineering and hiPSC-Derived 2D Disease Modeling Systems. | Rehbach K et al. | β | 2020 | β |
| Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells. | Powell SK et al. | β | 2020 | β |
| Modeling neuronal consequences of autism-associated gene regulatory variants with human induced pluripotent stem cells. | Ross PJ et al. | β | 2020 | β |
| Neuronal differentiation strategies: insights from single-cell sequencing and machine learning. | Konstantinides N et al. | β | 2020 | β |
| The innate immunity protein IFITM3 modulates Ξ³-secretase in Alzheimer's disease. | Hur JY et al. | β | 2020 | β |
| Transcription Factor-Based Fate Specification and Forward Programming for Neural Regeneration. | Flitsch LJ et al. | β | 2020 | β |
| Direct Neuronal Reprogramming Reveals Unknown Functions for Known Transcription Factors. | Colasante G et al. | β | 2019 | β |
| Human iPSC application in Alzheimer's disease and Tau-related neurodegenerative diseases. | Tcw J | β | 2019 | β |
| <i>CNTN5</i><sup>-</sup><i><sup>/+</sup></i>or <i>EHMT2</i><sup>-</sup><i><sup>/+</sup></i>human iPSC-derived neurons from individuals with autism develop hyperactive neuronal networks. | Deneault E et al. | β | 2019 | β |
| Molecular Interaction Networks to Select Factors for Cell Conversion. | Ouyang JF et al. | β | 2019 | β |
| mTOR and autophagy pathways are dysregulated in murine and human models of Schaaf-Yang syndrome. | Crutcher E et al. | β | 2019 | β |
| Neuronal impact of patient-specific aberrant NRXN1Ξ± splicing. | Flaherty E et al. | β | 2019 | β |
| Overexpression of NEUROG2 and NEUROG1 in human embryonic stem cells produces a network of excitatory and inhibitory neurons. | Lu C et al. | β | 2019 | β |
| Robust Generation of Person-Specific, Synchronously Active Neuronal Networks Using Purely Isogenic Human iPSC-3D Neural Aggregate Cultures. | Izsak J et al. | β | 2019 | β |
| Synergistic effects of common schizophrenia risk variants. | Schrode N et al. | β | 2019 | β |
| Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons. | Xue Y et al. | β | 2019 | β |
| Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons. | Engle SJ et al. | β | 2018 | β |
| Convergence of independent DISC1 mutations on impaired neurite growth via decreased UNC5D expression. | Srikanth P et al. | β | 2018 | β |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | β | 2018 | β |
| Inhibition of STEP<sub>61</sub> ameliorates deficits in mouse and hiPSC-based schizophrenia models. | Xu J et al. | β | 2018 | β |
| Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells. | LaMarca EA et al. | β | 2018 | β |
| Neuron-specific signatures in the chromosomal connectome associated with schizophrenia risk. | Rajarajan P et al. | β | 2018 | β |
| Application of CRISPR/Cas9 to the study of brain development and neuropsychiatric disease. | Powell SK et al. | β | 2017 | β |
| Discovery of Compounds that Positively Modulate the High Affinity Choline Transporter. | Choudhary P et al. | β | 2017 | β |
| Evaluating Synthetic Activation and Repression of Neuropsychiatric-Related Genes in hiPSC-Derived NPCs, Neurons, and Astrocytes. | Ho SM et al. | β | 2017 | β |
| Patient-derived hiPSC neurons with heterozygous CNTNAP2 deletions display altered neuronal gene expression and network activity. | Flaherty E et al. | β | 2017 | β |
| Personalized medicine in a dish: the growing possibility of neuropsychiatric disease drug discovery tailored to patient genetic variants using stem cells. | Brennand KJ | β | 2017 | β |
| Pluripotent stem cells in neuropsychiatric disorders. | Soliman MA et al. | β | 2017 | β |
| Prospects for Modeling Abnormal Neuronal Function in Schizophrenia Using Human Induced Pluripotent Stem Cells. | Prytkova I et al. | β | 2017 | β |
| Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder. | Watmuff B et al. | β | 2017 | β |
| THC Treatment Alters Glutamate Receptor Gene Expression in Human Stem Cell-Derived Neurons. | Obiorah IV et al. | β | 2017 | β |
| Coenzyme A corrects pathological defects in human neurons of PANK2-associated neurodegeneration. | Orellana DI et al. | β | 2016 | β |
| Human pluripotent stem cells. | Carpenedo RL et al. | β | 2016 | β |